Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses

American Journal of Veterinary Research

Volumn 58, Issue 11, 1997, Pages 1291-1299

  Baskett, Anne ^a   Barton, Michelle Henry ^a   Norton, Natalie ^a   Anders, Brendan ^a   Moore, James N ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FLUNIXIN MEGLUMINE; INTERLEUKIN 6; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOXANE B2; TUMOR NECROSIS FACTOR;

ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; FEVER; HORSE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PULSE RATE; RECTUM TEMPERATURE;

6-KETOPROSTAGLANDIN F1 ALPHA; ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY TEMPERATURE; CLONIXIN; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; ENDOTOXEMIA; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HEMODYNAMIC PROCESSES; HORSE DISEASES; HORSES; INTERLEUKIN-6; LEUKOCYTE COUNT; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOXANE B2; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

ANIMALIA; EQUIDAE; EQUUS CABALLUS; ESCHERICHIA COLI;

EID: 0030709336     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Meyers K, Reed S, Keck M, et al. Circulating endotoxin-like substance(s) and altered hemostasis in horses with gastrointestinal disorders: an interim report. Am J Vet Res 1982;43:2233-2238.
2. Moore JN, Morris DD. Endotoxemia and septicemia in horses: experimental and clinical correlates. J Am Vet Med Assoc 1992;200:1903-1914.
3. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-113.
4. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991; 113:981-986.
5. Ertel W, Morrison MH, Wang P, et al. The complex pattern of cytokines in sepsis: association between prostaglandins, cachectin and interleukins. Ann Surg 1991;214:141-148.
6. Shuster R, Traub-Dargatz J, Baxter G. Survey of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons regarding clinical aspects and treatment of endotoxemia in horses. J Am Vet Med Assoc 1997;210:87-92.
7. Moore JN, Garner HE, Shapland JE, et al. Prevention of endotoxin-induced arterial hypoxemia and lactic acidosis with flunixin meglumine in the conscious pony. Equine Vet J 1981;13:95-98.
8. Ewert KM, Fessler JF, Templeton CB, et al. Endotoxin induced hematologic and blood chemical changes in ponies: effects of flunixin meglumine, dexamethasone and prednisolone. Am J Vet Res 1985;46:24-30.
9. Semrad SD, Hardee GE, Hardee MM, et al. Low dose flunixin meglumine: effects on eicosanoid production and clinical signs induced by experimental endotoxemia in horses. Equine Vet J 1987;19:201-206.
10. Bottoms GE, Fessler JF, Roesel OF, et al. Endotoxin-induced hemodynamic changes in ponies: effects of flunixin meglumine. Am J Vet Res 1981;42:1514-1518.
11. 2 (epoprostenol), and the hemodynamic changes in equine endotoxin shock. Am J Vet Res 1982;43:999-1002.
12. Ward DS, Fessler JF, Bottoms GD, et al. Equine endotoxemia: cardiovascular, eicosanoid, blood chemical, and plasma enzyme alterations. Am J Vet Res 1987;48:1150-1156.
13. Henry M, Moore JN. Equine endotoxemia. In: Smith BP, ed. Large animal medicine. St Louis: CV Mosby, 1990;668-674.
14. MacKay RJ, Merritt AM, Zertuche JM, et al. Tumor necrosis factor activity in the circulation of horses given endotoxin. Am J Vet Res 1991;52:533-538.
15. Spatafora M, Chiappara G, D'Amico D, et al. Effect of indomethacin on the kinetics of tumor necrosis factor alpha release and tumor necrosis factor alpha gene expression by human blood monocytes. Pharm Res 1991;23:247-257.
16. Martich GD, Danner RL, Ceska M, et al. Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991;173:1021-1024.
17. Spinas GA, Bloesch D, Keller U, et al. Pretreatment with ibuprofen augments circulating tumor necrosis factor-α, interleukin-6, and elastase during acute endotoxemia. J Infect Dis 1991;163: 89-95.
18. Ertel W, Morrison MH, Meldrum DR, et al. Ibuprofen restores cellular immunity and decreases susceptibility to sepsis following hemorrhage. J Surg Res 1992;53:55-61.
19. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 1988;263:5380-5384.
20. Endres S, Whitaker RE, Ghorbani R, et al. Oral aspirin and ibuprofen increase cytokine induced synthesis of IL-1 beta and of tumor necrosis factor-alpha ex vivo. Immuniology 1996;87:264-270.
21. Kasid A, Director EP, Rosenberg SA. Regulation of interleukin-6 by 1L-2 and TF in human peripheral blood mononuclear cells. Ann NY Acad Sci 1989;557:564-566.
22. Dinarello CA, Cannon JG, Wolff SM, et el. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986;163:1433-1450.
23. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
24. Muller R. Hemorheology and peripheral vascular diseases: a new therapeutic approach. J Med 1981;12:209-235.
25. Tighe D, Moss R, Hynd J, et al. Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit Care Med 1990;18:184-189.
26. van Leenen D, van der Poll T, Levi M. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993;151:2318-2325.
27. Levi M, ten Cate H, Bauer K, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1993;93:114-120.
28. Barton MH, Moore JN. Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 1994;44:216-220.
29. Streiter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Comm 1988;155:1230-1235.
30. Schandene L, van den Bussche P, Crusiaux A, et al. Differential effects of pentoxifylline on the production of tumor necrosis factor-alpha and interleukin-6 by monocytes and T cells. Immuniology 1992;76:30-34.
31. 1 and ex-vivo endotoxin-induced tumor necrosis activity. J Vet Pharmacol Ther 1997;In press.
32. Lundblad R, Ekstrom P, Giercksky KE. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 1995;3:210-215.
33. Zabel P, Schonharting M, Schade U, et al. Effects of pentoxifylline in endoloxemia in human volunteers. Prog Clin Biol Res 1991;367:207-213.
34. Natanson C. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-783.
35. Katami Y, Nakao Y, Koizumi T. Regulation of tumor necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP. Immuniology 1988;64:719-724.
36. Barton MH, Moore JN, Norton N. The effects of pentoxifylline infusion on the response of horses to in vivo challenge with endotoxin. Am J Vet Res 1997;in press.
37. Morris DD, Crowe N, Moore JN. Correlation of clinical and laboratory data with serum tumor necrosis factor activity in horses with experimentally induced endotoxemia. Am J Vet Res 1990;51: 1935-1940.
38. Morris DD, Moore JN, Crowe N, et al. Effect of experimentally induced endotoxemia on serum interleukin-6 activity in horses. Am J Vet Res 1992;53:753-756.
39. Moore JN, Hardee MM, Hardee GE. Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor. Am J Vet Res 1986;47:110-113.
40. Ranby M, Noorman B, Wallen P. A sensitive assay for tissue plasminogen activator in plasma. Thromb Res 1982;27:743-749.
41. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983;31:427-436.
42. Collatos C, Barton MH, Prasse KW, et al. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases. J Am Vet Med Assoc 1995;207:465-470.
43. Fessler JF, Bottoms GD, Roesel OF, et al. Endotoxin-induced changes in hemograms, plasma enzymes, and blood chemical values in anesthetized ponies: effects of flunixin meglumine. Am J Vet Res 1982;43:140-144.
44. Cook JA, Wise WC, Halushka PV. Protective effect of a selective leukotriene antagonist in endotoxemia in the rat. J Pharmacol Exp Ther 1985;235:470-474.
45. Hand WL, Butera ML, King-Thompson NL, et al. Pentoxifylline modulation of plasma membrane functions in human polymorphonuclear leukocytes. Infect Immun 1989;57:3520-3526.
46. Bessler H, Gilgal M, Djaldetti M, et al. Effect of pentoxifylline on the phagocytic activity, cAMP levels and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 1986;40:747-754.
47. Templeton CB, Bottoms GD, Fessler JF, et al. Endotoxin-induced hemodynamic and prostaglandin changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Circ Shock 1987;23:231-240.
48. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997;336:912-918.
49. 1 and thromboxane B, in healthy volunteers. Prostaglandins Leukot Med 1986;22:191-200.
50. Masouye P, Gunning K, Pittet J-F, et al. Xanthine derivative HWA 138 attenuates hemodynamic and oxygen uptake dysfunction secondary to severe endotoxin shock in sheep. Circ Shock 1992;36: 113-119.
51. Fletcher JR, Ramwell PW. The effects of prostacyclin (PG12) on endotoxin shock and endotoxin-induced platelet aggregation in dogs. Circ Shock 1980;7:299-308.
52. Krausz MM, Utsunomiya T, Feverstein G. Prostacyclin reversal of lethal endotoxemia in dogs. J Clin Invest 1981;67:1118-1125.
53. Jarrett PEM, Moreland M, Browse NL. The effect of oxpentifylline on fibrinolytic activity and plasma fibrinogen levels. Curr Med Res Opin 1977;4:492-495.
54. 2) in conscious ponies. Am J Vet Res 1982;43:1128-1131.
55. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989;320: 1165-1171.
56. Morris DD. Physiology of hemostasis. In: Auer JA, ed. Equine surgery. Philadelphia: WB Saunders Co, 1993;55-59.
57. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-387.
58. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci 1995;88:587-594.
59. Bevilacqua MP, Schleef RR, Gimbrone MA, et al. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986;78:587-591.
60. Pralong G, Calandra T, Glauser MP, et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989;61:459-462.
61. Collatos C, Barton MH, Schleef R. Regulation of equine fibrinolysis in blood and peritoneal fluid based on a study of colic cases and induced endotoxemia. Equine Vet J 1994;26:474-481.
62. Emeis JJ, van den Hoogen CM. Pharmacological modulation of the endotoxin-induced increase in plasminogen activator inhibitor activity in rats. Blood Coagul Fibrinolysis 1992;3:375.
63. Emeis JJ, Hoekzema R, de Vos AF. Inhibiting interleukin-1 and tumor necrosis factor-α does not reduce induction of plasminogen activator inhibitor type-1 by endotoxin in rats in vivo. Blood 1995;85:115-120.
64. Levi M, ten Cate H, van der Poll T, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-120.
65. Tranquille N, Emeis JJ. The effect of pentoxifylline (Trental) and two analogues, BL194 and HWA 448, on the release of plasminogen activators and von Willebrand factor in rats. J Cardiovasc Pharmacol 1991;18:35-42.
66. Ambrus JL, Ambrus CM, Stadler S. Potentiation of thrombolytic therapy by enzyme combinations and with aspirin or pentoxifylline. J Med 1994;25:145-161.
67. Levin RI, Harpel PC, Weil D, et al. Aspirin inhibits vascular plasminogen activator activity in vivo. J Clin Invest 1984;74:571-580.
68. Koh SCL, Pua HL, Tay DHB, et al. The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without Keterolac infusion. Thromb Res 1995;79:501-514.
69. MacKay RJ, Lester GD. Induction of the acute-phase cytokine, hepatocyte-stimulating factor/interleukin-6, in the circulation of horses treated with endotoxin. Am J Vet Res 1992;53:1285-1289.
70. Morris DD, Moore JN, Crowe N. Serum tumor necrosis factor activity in horses with colic attributable to gastrointestinal tract disease. Am J Vet Res 1991;52:1565-1569.
71. Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
72. 2 in resting macrophages. Biochem Biophys Res Comm 1986;136:94-101.
73. Cargile JL, MacKay RJ, Dankert JR, et al. Effects of tumor necrosis factor blockade on interleukin 6, lactate, thromboxane, and prostacyclin responses in Miniature horses given endotoxin. Am J Vet Res 1995;56:1445-1450.
74. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-394.
75. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor, Circ Shock 1990;31:171-181.
76. Knudson PJ, Dinarello CA, Strom TB. Prostaglandins postranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 1986;137:3189-3194.
77. 2 of TNF and IL-1 production by human monocytes. Immuniology 1989;66:376-383.
78. Shalaby MR, Waage A, Aarden L, et al. Endotoxin, tumor necrosis factor-α, and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol 1989;53:488-498.
79. Beck RR, Abel FL. Effect of ibuprofen on the course of canine endotoxin shock. Circ Shack 1987;23:59-70.
80. Coran AG, Drongowksi RA, Paik JJ, et al. Ibuprofen intervention in canine septic shock: reduction of pathophysiology without decreased cytokines. J Surg Res 1992;53:272-279.
81. Gibson RL, Truog WE, Henderson WR, et al. Group B streptococcal sepsis in piglets: effect of combined pentoxifylline and indomethacin pretreatment. Pediatr Res 1992:311;222-227.